Ki-Chul Sung1, Sarah H Wild2, Christopher D Byrne3. 1. Division of Cardiology, Department of Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Electronic address: kcmd.sung@samsung.com. 2. Centre for Population Health Sciences, Lothian Place University of Edinburgh, UK. 3. Endocrinology and Metabolism Unit, IDS Building, Southampton General Hospital, University of Southampton, MP 887, Southampton, UK. Electronic address: c.d.byrne@soton.ac.uk.
Abstract
BACKGROUND & AIMS: Approximately 50% of hypertensive patients have non-alcoholic fatty liver disease (NAFLD), but whether change in fatty liver status over time modifies risk of developing hypertension is uncertain. Our aim was to determine whether a change in fatty liver status (either development of new fatty liver, or resolution of existing fatty liver) over five years modified risk of incident hypertension at five year follow-up. METHODS: 11,448 patients without hypertension were examined at baseline and at five year follow-up, using a retrospective cohort study design. Fatty liver status (absent or present) was assessed at baseline and follow-up using standard ultrasound criteria. Adjusted odds ratios (aOR) and 95% confidence intervals (CIs) for incident hypertension at follow-up were estimated controlling for potential confounders, compared to the reference group (patients who did not have fatty liver at either baseline or follow-up). RESULTS: 911 patients developed incident hypertension. Incident fatty liver developed during follow-up in 1418 patients and fatty liver at baseline resolved during follow-up in 684 patients. Developing incident fatty liver was associated with incident hypertension, even after adjustment for multiple confounders (aOR=1.60 (95% CI 1.30, 1.96; p<0.001). Further adjustment for change in body mass index between baseline and follow-up only slightly attenuated this association (aOR=1.36 (95% CI 1.10, 1.67; p=0.004). With resolution of fatty liver at follow-up, risk of incident hypertension was not different from the reference group (aOR=1.21 (95% CI 0.90, 1.63; p=0.21). CONCLUSIONS: Development of incident fatty liver is associated with increased risk of hypertension.
BACKGROUND & AIMS: Approximately 50% of hypertensivepatients have non-alcoholic fatty liver disease (NAFLD), but whether change in fatty liver status over time modifies risk of developing hypertension is uncertain. Our aim was to determine whether a change in fatty liver status (either development of new fatty liver, or resolution of existing fatty liver) over five years modified risk of incident hypertension at five year follow-up. METHODS: 11,448 patients without hypertension were examined at baseline and at five year follow-up, using a retrospective cohort study design. Fatty liver status (absent or present) was assessed at baseline and follow-up using standard ultrasound criteria. Adjusted odds ratios (aOR) and 95% confidence intervals (CIs) for incident hypertension at follow-up were estimated controlling for potential confounders, compared to the reference group (patients who did not have fatty liver at either baseline or follow-up). RESULTS: 911 patients developed incident hypertension. Incident fatty liver developed during follow-up in 1418 patients and fatty liver at baseline resolved during follow-up in 684 patients. Developing incident fatty liver was associated with incident hypertension, even after adjustment for multiple confounders (aOR=1.60 (95% CI 1.30, 1.96; p<0.001). Further adjustment for change in body mass index between baseline and follow-up only slightly attenuated this association (aOR=1.36 (95% CI 1.10, 1.67; p=0.004). With resolution of fatty liver at follow-up, risk of incident hypertension was not different from the reference group (aOR=1.21 (95% CI 0.90, 1.63; p=0.21). CONCLUSIONS: Development of incident fatty liver is associated with increased risk of hypertension.
Authors: Robin H Isaacson; Juliane I Beier; Nicholas Kh Khoo; Bruce A Freeman; Zachary Freyberg; Gavin E Arteel Journal: J Nutr Biochem Date: 2020-04-08 Impact factor: 6.048
Authors: Alina M Allen; Terry M Therneau; Joseph J Larson; Alexandra Coward; Virend K Somers; Patrick S Kamath Journal: Hepatology Date: 2018-03-23 Impact factor: 17.425
Authors: Jiantao Ma; Shih-Jen Hwang; Alison Pedley; Joseph M Massaro; Udo Hoffmann; Raymond T Chung; Emelia J Benjamin; Daniel Levy; Caroline S Fox; Michelle T Long Journal: J Hepatol Date: 2016-10-10 Impact factor: 25.083
Authors: Adeel A Butt; Peng Yan; Vincent Lo Re; David Rimland; Matthew B Goetz; David Leaf; Matthew S Freiberg; Marina B Klein; Amy C Justice; Kenneth E Sherman Journal: JAMA Intern Med Date: 2015-02 Impact factor: 21.873
Authors: A G Laurinavicius; M S Bittencourt; M J Blaha; F C Nary; N M Kashiwagi; R D Conceiçao; R S Meneghelo; R R Prado; J A M Carvalho; K Nasir; R S Blumenthal; R D Santos Journal: QJM Date: 2016-01-19